EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

EKF Diagnostics Holdings (EKDHF) fair value: what the stock is really worth

As of Sep 25, 2026: fair value of EKF Diagnostics Holdings $0.30, price $0.34, upside -11.9%, quality 71 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US · ISIN GB0031509804

ED EKF Diagnostics Holdings logo Thin data Sep 24, 2026

EKF Diagnostics Holdings

EKDHF · US

Overvalued / MonitorQuality growthQuality is not strong enough to offset the price risk.

!Fair value $0.3000 · Overvalued (−11.9%)
✓Quality 71/100
!Weak Growth (revenue 5y −4.6 %/yr)
!Thin margins · 4.1% net margin (TTM)
✓Low debt · generates free cash flow
!Narrow moat 37/100
!Evidence only low, so the estimate is less certain
Watch EKF Diagnostics Holdings for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$1.05 $0.1333 Fair Value $0.3000 Sep 2015 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $0.1333 – $1.05 · fair‑value band $0.2600 – $0.3600 · the $0.3405 price screens above the $0.3000 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 24, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally.

Show more

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm analyzer; Hemo Control, a hemoglobin analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. It also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab HbA1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test HbA1c, fully automated hemoglobin A1c analyzer for the monitoring and management of diabetes; and STAT-Site W Beta-Hydroxybutyrate analyzer. In addition, the company offers Creamatocrit Plus, a breast milk analyzer; QuPID and True20 pregnancy tests; Lactate Scout Vet, a handheld lactate analyzer for veterinary care; Hemo Vet, a point-of-care hemoglobin and hematocrit analyzer; Lactate Scout Sport, a lactate analyzer for sports performance; Biosen series for sports; and EKF Link, a data management solution that integrates point-of-care analyzers. Further, it offers Beta-Hydroxybutyrate LiquiColor for monitoring ketosis; RaPET, a range of immunoassay kits; QuStick Strep A for Strep A infection treatment; Hema-Screen Lab Pack for detection of colorectal cancer; PrimeStore MTM, a molecular transport medium that preserves and stabilizes DNA and RNA; Uri-Trak 120M urine analyzer; and clinical chemistry reagents, controls, and standards. Additionally, the company provides precision fermentation, custom bioprocessing, and contract manufacturing solutions; and diagnostic enzymes that include arylacylamidase, beta-hydroxybutyrate dehydrogenase, and salicylate hydroxylase. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.

Stock analysis

EKF Diagnostics Holdings (EKDHF) currently trades at $0.3405, while our model-based Fair Value estimate is $0.3000, 11.9% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of $0.3900 per share, and 9 of the 24 models we run sit above the $0.3405 price.

Bear case: the Earnings-Based group reads lowest at $0.0800, and 15 of the 24 models stay below the price. Evidence for this calculation is low.

Scenario range: $0.2600 (bear) to $0.3600 (bull), the price of $0.3405 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 71/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

EKF Diagnostics Holdings reported revenue of £51.6M in FY2025 versus £81.8M in FY2021, a compound −10.9%/yr. Reported net income was £2.1M in FY2025, compounding −39.5%/yr from FY2021.

Key figures

Market cap $153M · P/E ratio 34.1 · P/S ratio 1.40 · EPS (TTM) $0.0100 · Dividend yield 3.6% · Net margin 4.1% · Return on equity 3.5% · Return on assets (EBIT) 8.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 20% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −12%, EKDHF screens richer than that median.

Fair Value models

Bear $0.2600 Fair Value $0.3000 Bull $0.3600
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.0076 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $0.2900 $0.4300 $0.6300 80
Growth DCF $0.2800 $0.4000 $0.5700 79
Owner Earnings $0.2200 $0.3300 $0.4800 76
All 24 models by family
DCF Models
FCF DCF $0.2900 $0.4300 $0.6300 80
Owner Earnings $0.2200 $0.3300 $0.4800 76
5Y Revenue Exit $0.2600 $0.3900 $0.5800 72
5Y EBITDA Exit $0.3600 $0.6100 $0.9100 74
5Y P/E Exit $0.2000 $0.2800 $0.3700 71
10Y Revenue Exit $0.2600 $0.3800 $0.5600 66
10Y EBITDA Exit $0.3200 $0.5100 $0.8000 67
10Y P/E Exit $0.2300 $0.3100 $0.4100 65
Earnings-Based
Graham-Dodd $0.0400 $0.2100 $0.2900 64
Lynch FV $0.0500 $0.0800 $0.1000 61
PEG = 1.0 $0.0500 $0.0800 $0.1000 57
EPV $0.1300 $0.1300 $0.1400 74
Multiples
P/E Multiple $0.1100 $0.1400 $0.1800 63
P/S Multiple $0.0800 $0.1100 $0.1400 58
P/B Multiple $0.0800 $0.1100 $0.1400 55
EV/EBIT $0.3200 $0.4100 $0.5100 66
EV/EBITDA $0.4500 $0.5800 $0.7200 67
EV/Revenue $0.2400 $0.3300 $0.4100 54
Asset-Based
NCAV (Graham) $0.1100 $0.1400 $0.2100 54
Growth DCF
Growth DCF $0.2800 $0.4000 $0.5700 79
Rev-Margin DCF $0.2600 $0.3900 $0.5700 72
Economic Profit
Residual Income $0.1400 $0.1300 $0.1300 71
ROIC Compounder $0.1300 $0.1300 $0.1400 72
Growth Earnings
Growth-Adj P/E $0.0900 $0.1300 $0.1700 67

Open the full fair value analysis →

Notify me when EKDHF reaches fair value

Put EKDHF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 71/100

Of which business quality 73 · Market factors (momentum, volatility) 48

Profitability 37
Margins and returns on capital today
Quality Growth 52
Are margins and returns improving?
Cashflow 80
Earnings quality: real cash, not paper profit
Fin. Strength 93
Balance sheet, leverage, solvency risk
Investment 98
Disciplined investing over empire-building
Low Volatility 77
Calm price path (market factor)
Momentum 39
Price trend over the last 3–12 months (market factor)
52W Momentum 30
Distance to the 52-week high (market factor)
Net Issuance 91
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+2.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.6%
Start year 2020 (pandemic). Over 10 years: +5.5% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.4%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−24.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−27.9%
Dividend (yield on the price)3.6%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.26% → 14%

Growth Forecast

Price in line with expectations
The price assumes more growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+3.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+6.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in GBP, UK: IMF forecast 2.3% a year to 2030, 3.3% from 2016 to 2025) that is about +1.5% a year for the price and +3.6% for the forecasts.
Forecast 2026 (sales)+5.9%
Forecast 2027 (sales)+6.9%
Projected 2028 (sales)+6.3%
Projected 2029 (sales)+5.7%
Projected 2030 (sales)+5.1%

EKDHF screens overvalued: fair value 12% below the price. Compare with Abbott Laboratories, →

Compare EKF Diagnostics Holdings with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 349 stocks

Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 71 · Top 25%
Fair Value upside −56.4% · Below median
Profitability
Return on equity (TTM) 3.5% · Above median
Return on assets 5.4% · Top 25%
Net margin (TTM) 4.1% · Below median
Operating margin (TTM) 12.9% · Above median
Growth and dividend
Revenue growth 5.4% · Below median
Dividend yield (TTM) 3.6% · Top 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (TTM) 34.1× · Pricier than median
P/B 2.16× · Pricier than median
P/S (TTM) 2.90× · Pricier than median
P/FCF 18.3× · Cheaper than median
EV/EBITDA 13.1× · Cheaper than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $98.83 $74.79 −24%
Medtronic plc MDT $87.09 $65.61 −25%
Stryker Corporation SYK $278.77 $306.65 +10%
Boston Scientific Corporation BSX $43.65 $48.02 +10%
Edwards Lifesciences Corporation EW $85.19 $81.94 −4%
Siemens Healthineers AG SHL €37.86 €35.19 −7%
DexCom, Inc DXCM $86.68 $95.35 +10%
GE HealthCare Technologies Inc GEHC $66.63 $70.37 +6%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥153.86 ¥169.25 +10%
Koninklijke Philips N.V PHIA €21.87 €15.23 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

EKF Diagnostics Holdings · Fair Value
$0.3000 −12%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "EKF Diagnostics Holdings Fair Value". https://www.fairvalue-calculator.com/stock/EKDHF

Frequently asked questions

Is EKF Diagnostics Holdings (EKDHF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.3000 versus the last price from Sep 25, 2026 of $0.3405, about −12% upside (overvalued).
What is the fair value of EKDHF?
Our model-based fair value for EKF Diagnostics Holdings is $0.3000 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $0.3405.
What is the quality score of EKDHF?
EKF Diagnostics Holdings has a Quality Score of 71/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for EKF Diagnostics Holdings (EKDHF)?
Our model-based price target is the fair value of $0.3000 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario $0.2600, optimistic scenario $0.3600. It is a calculation from audited fundamentals, not an analyst target.
What is the EKF Diagnostics Holdings stock forecast for 2026?
Our models put fair value at $0.3000, about −12% upside versus the last price from Sep 25, 2026 of $0.3405 (overvalued). Cautious scenario $0.2600, optimistic scenario $0.3600. The calculation is refreshed regularly with new filings.
What is the revenue of EKF Diagnostics Holdings (EKDHF)?
EKF Diagnostics Holdings reported trailing-twelve-month revenue of about £51.6M (latest available figure, as of Sep 24, 2026).
Does EKF Diagnostics Holdings pay a dividend?
EKF Diagnostics Holdings currently shows a dividend yield of about 3.65% relative to its recent price (as of Sep 24, 2026).
What growth is priced into EKF Diagnostics Holdings (EKDHF)?
For today's price to be fair in a discounted-cash-flow model, EKF Diagnostics Holdings would have to grow free cash flow by +3.8 % per year for five years (discount rate 11.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -4.6 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of EKDHF use?
Our models discount EKF Diagnostics Holdings at 11.2 %: a base by market capitalisation (micro), damped by beta 0.52, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For EKF Diagnostics Holdings that is +3.8 % per year a year over ten years, using the same discount rate (11.2 %) and the same formula as our fair value.
How much growth has EKF Diagnostics Holdings (EKDHF) delivered so far?
Over the past 5 years revenue at EKF Diagnostics Holdings grew -4.6 % a year. The price currently implies +3.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of EKF Diagnostics Holdings (EKDHF) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into EKF Diagnostics Holdings (+3.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of EKF Diagnostics Holdings (EKDHF)?
The free-cash-flow yield on the price is 7.09 %: that much free cash flow EKF Diagnostics Holdings produces per unit of market value. When it exceeds the discount rate of our models (11.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of EKF Diagnostics Holdings (EKDHF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For EKF Diagnostics Holdings it is $0.3000 per share (as of Sep 24, 2026), against a price of $0.3405. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is EKF Diagnostics Holdings stock overvalued or undervalued in 2026?
As of Sep 24, 2026, EKDHF trades above its calculated fair value: price $0.3405, fair value $0.3000, a gap of about −12% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EKDHF?
No. The price is what the market pays today ($0.3405); the fair value is what the company's own numbers justify ($0.3000). For EKF Diagnostics Holdings the two are $0.0405 per share apart. That gap is exactly why we show both numbers side by side.
How much is EKF Diagnostics Holdings worth?
The market values EKF Diagnostics Holdings at about $153M (market capitalisation, as of Sep 24, 2026). Per share that is $0.3405; our models calculate a fair value of $0.3000 per share.
What do the bullish and bearish scenarios say about EKDHF?
Our models span a range for EKF Diagnostics Holdings: cautious scenario $0.2600, base $0.3000, optimistic $0.3600 per share (as of Sep 24, 2026, price $0.3405). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of EKDHF?
EKF Diagnostics Holdings trades at a price-to-earnings ratio of 34.1 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.3000 is built from several models across several years. Other multiples: P/B 2.2, P/S 2.9, EV/EBITDA 13.1.
How solid is the balance sheet of EKF Diagnostics Holdings (EKDHF)?
Balance-sheet figures for EKF Diagnostics Holdings (as of Sep 24, 2026): return on equity 3.5%. They feed the Quality Score of 71/100, which measures business quality independently of the share price.
How far is EKDHF from its 52-week high?
EKF Diagnostics Holdings trades at $0.3405, about 20% below its 52-week high of $0.4236 and 16% above the low of $0.2939 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.3000 is for.
Which stocks are comparable to EKF Diagnostics Holdings?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is EKF Diagnostics Holdings stock attractive at the current price?
The data as of Sep 24, 2026: price $0.3405, calculated fair value $0.3000 (−12%), Quality Score 71/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EKDHF calculated?
We run EKF Diagnostics Holdings through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.3000, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. EKF Diagnostics Holdings itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of EKF Diagnostics Holdings (EKDHF)?
The latest price we hold is from Sep 25, 2026 and stands at $0.3405. Our model-based fair value is $0.3000, about −12% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with EKF Diagnostics Holdings right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of EKF Diagnostics Holdings

How large is the market capitalisation of EKF Diagnostics Holdings (EKDHF)?
The market capitalisation of EKF Diagnostics Holdings is $153M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of EKF Diagnostics Holdings (EKDHF)?
The price-to-sales ratio of EKF Diagnostics Holdings is 1.40 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of EKF Diagnostics Holdings (EKDHF)?
Earnings per share at EKF Diagnostics Holdings are $0.0100 (price ÷ EPS = P/E 34.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of EKF Diagnostics Holdings (EKDHF)?
The dividend yield of EKF Diagnostics Holdings is 3.6% (payout 124%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of EKF Diagnostics Holdings (EKDHF)?
The net margin of EKF Diagnostics Holdings is 4.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of EKF Diagnostics Holdings (EKDHF)?
The return on equity (ROE) of EKF Diagnostics Holdings is 3.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of EKF Diagnostics Holdings (EKDHF)?
On an EBIT basis the return on assets of EKF Diagnostics Holdings is 8.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of EKF Diagnostics Holdings (EKDHF)?
The operating margin of EKF Diagnostics Holdings is 12.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at EKF Diagnostics Holdings (EKDHF)?
Revenue at EKF Diagnostics Holdings is growing +5.4% versus a year earlier (3y avg −8.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at EKF Diagnostics Holdings (EKDHF)?
Earnings per share at EKF Diagnostics Holdings are growing −96.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does EKF Diagnostics Holdings (EKDHF) hold?
EKF Diagnostics Holdings holds more cash than debt, £14.4M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch EKF Diagnostics Holdings in the live analysis

One click puts EKF Diagnostics Holdings on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.